Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | HTR1D | P28221 | 6/20 | 0.72 |
| ▸ | LTA4H | P09960 | 7/20 | 0.70 |
| ▸ | PLA2G2A | P14555 | 7/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
| ▸ | HTR1B | P28222 | 3/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARD | Q03181 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988545 | 0.89 | HTR1D (0.78) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL29007183 | 0.89 | TRPM8 (0.76) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL29617411 | 0.89 | TRPM8 (0.76) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL24183187 | 0.87 | TRPM8 (0.74) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL6987351 | 0.87 | SLC6A4 (0.77) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL28100769 | 0.86 | TRPM8 (0.72) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL6982859 | 0.86 | SLC6A4 (0.75) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL5473262 | 0.85 | TRPM8 (0.67) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL19243092 | 0.85 | LTA4H (0.69) | TRPM8KDM4EMAPTHTR1DLTA4H | |
| SCHEMBL5648586 | 0.85 | HTR1D (0.78) | TRPM8KDM4EMAPTHTR1DLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751897-B1 | Derivatives of Bodipy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1620088-A4 | INDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | BAYER PHARMACEUTICALS CORP (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1620088-A2 | INDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Bayer Pharmaceuticals Corporation (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098498-A2 | INDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | TRPM8 3756/4885KDM4E 1373/4885MAPT 1349/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | TRPM8 3756/4885KDM4E 1373/4885MAPT 1349/4885 |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | TRPM8 4459/4885KDM4E 3232/4885MAPT 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.